Beyond peptides and mAbs - Current status and future perspectives for biotherapeutics with novel constructs

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S4-S20

  Aldeghaither, Dalal ^a   Smaglo, Brandon G ^b   Weiner, Louis M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

antibodies; antibody engineering; immunoconjugate; peptides

Indexed keywords

AFLIBERCEPT; ALEMTUZUMAB; ANTIBODY CONJUGATE; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CELL PENETRATING PEPTIDE; DENOSUMAB; ECALLANTIDE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IPILIMUMAB; KALLIKREIN; LUCATUMUMAB; MONOCLONAL ANTIBODY; NANOBODY; OCRELIZUMAB; OFATUMUMAB; PANITUMUMAB; PEPTIDE; PERTUZUMAB; RAMUCIRUMAB; RITUXIMAB; SOMATOSTATIN DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; BIOLOGICAL PRODUCT;

ANGIONEUROTIC EDEMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER THERAPY; GENETIC ENGINEERING; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; PEPTIDES;

EID: 84923374362     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.407     Document Type: Article

References (207)

1. Ehrlich P, Bolduan C,. Collected Studies on Immunity. 1st ed. New York: John Wiley & Sons; 1906.
2. Strebhardt K, Ullrich A,. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8 (6): 473-480. doi: 10.1038/nrc2394.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61 (2): 69-90. doi: 10.3322/caac.20107.
4. Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K,. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol. 2002; 46 (11): 741-749.
5. Thundimadathil J,. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids. 2012; 2012 (1): 967347-967313. doi: 10.1155/2012/967347.
6. Kakde D, Jain D, Shrivastava V, Kakde R, Patil AT,. Cancer therapeutics-Opportunities, challenges and advances in drug delivery. J Appl Pharm Sci. 2011; 1 (09): 1-10.
7. Vogelstein B, Kinzler KW,. Cancer genes and the pathways they control. Nat Med. 2004; 10 (8): 789-799. doi: 10.1038/nm1087.
8. Folkman J,. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1 (1): 27-31.
9. Enbäck J, Laakkonen P,. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans. 2007; 35 (Pt 4): 780-783. doi: 10.1042/BST0350780.
10. Dorsam RT, Gutkind JS,. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007; 7 (2): 79-94. doi: 10.1038/nrc2069.
11. Weiner LM, Surana R, Wang S,. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010; 10 (5): 317-327. doi: 10.1038/nri2744.
12. Hajela K,. Structure and function of Fc receptors. Biochem Educ. 1991; 19 (2): 50-57. doi: 10.1016/0307-4412(91)90002-P.
13. Roopenian DC, Akilesh S,. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7 (9): 715-725. doi: 10.1038/nri2155.
14. Chames P, Van Regenmortel M, Weiss E, Baty D,. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009; 157 (2): 220-233. doi: 10.1111/j.1476-5381.2009.00190.x.
15. Köhler G, Milstein C,. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256 (5517): 495-497. doi: 10.1038/256495a0.
16. Shawler DL, Bartholomew R, Smith LM, Dillman RO,. Human immune responce to multiple injections of murine monoclonal IgG. J Immunol. 1985; 135 (2): 1530-1535.
17. Khazaeli MB, Conry RM, LoBuglio AF,. Human immune response to monoclonal antibodies. J Immunother. 1994; 15 (1): 42-52. doi: 10.1097/00002371-199401000-00006.
18. Robinson MK, Weiner LM, Adams GP,. Improving monoclonal antibodies for cancer therapy. Drug Dev Res. 2004; 61 (3): 172-187. doi: 10.1002/ddr.10345.
19. Mould DR, Sweeney KRD,. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel. 2007; 10 (1): 84-96.
20. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998; 9 (9): 995-1001.
21. Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350 (25): 2572-2581. doi: 10.1056/NEJMoa032534.
22. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54 (5): 1390-1400. doi: 10.1002/art.21778.
23. Becerra E, Cambridge G, la Torre de I, Leandro MJ,. Long-term safety of rituximab in patients with rheumatoid arthritis. Intern J Clin Rheumatol. 2012; 7 (4): 383-390. doi: 10.2217/ijr.12.31.
24. Weiner LM, Murray JC, Shuptrine CW,. Antibody-based immunotherapy of cancer. Cell. 2012; 148 (6): 1081-1084. doi: 10.1016/j.cell.2012.02.034.
25. Swers JS, Kellogg BA, Wittrup KD,. Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res. 2004; 32 (3): e36-e36. doi: 10.1093/nar/gnh030.
26. Crameri A, Cwirla S, Stemmer WP,. Construction and evolution of antibody-phage libraries by DNA shuffling. Nat Med. 1996; 2 (1): 100-102.
27. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G,. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (NY). 1992; 10 (7): 779-783.
28. Adams GP, Schier R, Marshall K, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998; 58 (3): 485-490.
29. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001; 61 (12): 4750-4755.
30. Reiter Y,. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 1998; 16 (12): 513-520. doi: 10.1016/S0167-7799(98)01226-8.
31. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM,. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol. 2007; 179 (5): 2815-2823.
32. Ruf P, Lindhofer H,. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001; 98 (8): 2526-2534.
33. Nimmerjahn F, Ravetch JV,. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun. 2012; 12: 13.
34. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. PNAS. 2006; 103 (11): 4005-4010. doi: 10.1073/pnas.0508123103.
35. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001; 276 (9): 6591-6604. doi: 10.1074/jbc.M009483200.
36. Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv Enzyme Regul. 2008; 48 (1): 152-164. doi: 10.1016/j.advenzreg.2007.11.011.
37. Moore GL, Chen H, Karki S, Lazar GA,. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mabs. 2010; 2 (2): 181-189.
38. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N,. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009; 100 (9): 1566-1572. doi: 10.1111/j.1349-7006.2009.01222.x.
39. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010; 21 (9): 1870-1876. doi: 10.1093/annonc/mdq027.
40. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10 (9): 942-949. doi: 10.1038/nm1093.
41. Vaccaro C, Zhou J, Ober RJ, Ward ES,. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005; 23 (10): 1283-1288. doi: 10.1038/nbt1143.
42. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12 (4): 252-264. doi: 10.1038/nrc3239.
43. Yao S, Zhu Y, Chen L,. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013; 12 (2): 130-146. doi: 10.1038/nrd3877.
44. Teicher BA, Chari RVJ,. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011; 17 (20): 6389-6397. doi: 10.1158/1078-0432.CCR-11-1417.
45. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001; 7 (6): 1490-1496.
46. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of southwest oncology group study S0106: an International intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Ann. 2009; 114. Abstract 790.
47. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68 (22): 9280-9290. doi: 10.1158/0008-5472. CAN-08-1776.
48. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, capecitabine. J Clin Oncol. 2012; 30 (26): 3234-3241. doi: 10.1200/JCO.2011.40.5902.
49. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367 (19): 1783-1791. doi: 10.1056/NEJMoa1209124.
50. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30 (18): 2190-2196. doi: 10.1200/JCO.2011.38.0402.
51. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30 (18): 2183-2189. doi: 10.1200/JCO.2011.38.0410.
52. Ricart ADA,. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011; 17 (20): 6417-6427. doi: 10.1158/1078-0432.CCR-11-0486.
53. Maric G, Rose AA, Annis MG, Siegel PM,. Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther. 2013; 6: 839-852. doi: 10.2147/OTT.S44906.
54. Hamid O, Sznol M, Pavlick AC, et al. Frequent dosing and GPNMB expression with CDX011 (CR011vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. J Clin Oncol. 2010; 28 (15s). Abstract 8525.
55. Woll P, Lorigan P, O'Brien M, et al. Abstract B237: Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC). Mol Cancer Ther. 2009; 8 (Supplement 1): B237. doi: 10.1158/1535-7163.TARG-09-B237.
56. Kreitman RJ, Fitzgerald DJP, Pastan I,. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma. 2009; 50 (Suppl 1): 32-37. doi: 10.3109/10428190903142216.
57. Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012; 30 (15): 1822-1828. doi: 10.1200/JCO.2011.38.1756.
58. Schrama D, Reisfeld RA, Becker JC,. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006; 5 (2): 147-159. doi: 10.1038/nrd1957.
59. Pasche N, Neri D,. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today. 2012; 17 (11-12): 583-590. doi: 10.1016/j.drudis.2012.01.007.
60. Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood. 2002; 99 (5): 1659-1665.
61. Sondel PM, Gillies SD,. Current and potential uses of immunocytokines as cancer immunotherapy. Antibodies. 2012; 1 (3): 149-171. doi: 10.3390/antib1020149.
62. Borsi L, Balza E, Carnemolla B, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood. 2003; 102 (13): 4384-4392. doi: 10.1182/blood-2003-04-1039.
63. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol. 2002; 20 (3): 264-269. doi: 10.1038/nbt0302-264.
64. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D,. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther. 2007; 9 (1): R9. doi: 10.1186/ar2115.
65. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20 (15): 3262-3269. doi: 10.1200/JCO.2002.11.017.
66. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001; 19 (19): 3918-3928.
67. Steiner M, Neri D,. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res. 2011; 17 (20): 6406-6416. doi: 10.1158/1078-0432.ccr-11-0483.
68. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R,. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 1994; 7 (9): 1129-1135.
69. Greenberg AS, Steiner L, Kasahara M, Flajnik MF,. Isolation of a shark immunoglobulin light chain cDNA clone encoding a protein resembling mammalian kappa light chains: implications for the evolution of light chains. PNAS. 1993; 90 (22): 10603-10607.
70. Rumfelt LL, McKinney EC, Taylor E, Flajnik MF,. The development of primary and secondary lymphoid tissues in the nurse shark Ginglymostoma cirratum: B-cell zones precede dendritic cell immigration and T-cell zone formation during ontogeny of the spleen. Scand J Immunol. 2002; 56 (2): 130-148.
71. Muyldermans S,. Nanobodies: Natural single-domain antibodies. Annu Rev Biochem. 2013; 82 (1): 775-797. doi: 10.1146/annurev-biochem-063011-092449.
72. Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G,. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989; 341 (6242): 544-546. doi: 10.1038/341544a0.
73. Pereira B, Benedict CR, Le A, Shapiro SS, Thiagarajan P,. Cardiolipin binding a light chain from lupus-prone mice †,‡. Biochemistry. 1998; 37 (5): 1430-1437. doi: 10.1021/bi972277q.
74. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM,. Domain antibodies: proteins for therapy. Trends Biotechnol. 2003; 21 (11): 484-490. doi: 10.1016/j.tibtech.2003.08.007.
75. Gay RD, Clarke AW, Elgundi Z, et al. Anti-TNFα domain antibody construct CEP-37247: full antibody functionality at half the size. mabs. 2010; 2 (6): 625-638. doi: 10.4161/mabs.2.6.13493.
76. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM,. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004; 279 (52): 53907-53914. doi: 10.1074/jbc.M407888200.
77. Müller D, Müller D, Kontermann RE, Kontermann PRE,. Bispecific Antibodies for cancer immunotherapy. BioDrugs. 2010; 24 (2): 89-98. doi: 10.2165/11530960-000000000-00000.
78. Rossi EA, Sharkey RM, McBride W, et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res. 2003; 9 (10 Pt 2): 3886S-3896S. doi: 10.1016/0161-5890(95)00080-1.
79. Baeuerle PA, Kufer P, Bargou R,. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009; 11 (1): 22-30.
80. Kellner C, Bruenke J, Stieglmaier J, et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother. 2008; 31 (9): 871-884. doi: 10.1097/CJI.0b013e318186c8b4.
81. Rader C,. DARTs take aim at BiTEs. Blood. 2011; 117 (17): 4403-4404. doi: 10.1182/blood-2011-02-337691.
82. Moore PAP, Moore PA, Zhang W, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. 2011; 117 (17): 4542-4551. doi: 10.1182/blood-2010-09-306449.
83. Mølhøj M, Crommer S, Brischwein K, et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol. 2007; 44 (8): 1935-1943. doi: 10.1016/j.molimm.2006.09.032.
84. Baeuerle PA, Reinhardt C, Kufer P,. BiTE: a new class of antibodies that recruit T-cells. Drugs Future. 2008; 33 (2): 137.
85. Rothe A, Younes A, Reiners KS, et al. A phase I study with the bispecific anti-CD30 x anti-CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. ASH Ann Meeting Abstracts. 2011; 118 (21): 3709.
86. Guo F, Das S, Mueller BM, Barbas CF, Lerner RA, Sinha SC,. Breaking the one antibody-one target axiom. PNAS. 2006; 103 (29): 11009-11014. doi: 10.1073/pnas.0603822103.
87. Wu B, Sun Y-N,. Pharmacokinetics of peptide-Fc fusion proteins. J Pharm Sci. 2013; 103 (1): 53-64. doi: 10.1002/jps.23783.
88. Rader C,. Chemically programmed antibodies. Trends Biotechnol. 2014; 32 (4): 186-197. doi: 10.1016/j.tibtech.2014.02.003.
89. Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014; 22 (5): 1217-1222. doi: 10.1007/s00520-013-2074-2.
90. Borghouts C, Kunz C, Groner B,. Current strategies for the development of peptide-based anti-cancer therapeutics. J Peptide Sci. 2005; 11 (11): 713-726. doi: 10.1002/psc.717.
91. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM,. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 1985; 313 (5999): 231-233.
92. Crawford ED,. Hormonal therapy in prostate cancer: historical approaches. Rev Urol. 2004; 6 (Suppl 7): S3-S11.
93. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z,. Peptide analogs in the therapy of prostate cancer. Prostate. 2000; 45 (2): 158-166.
94. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993; 72 (1): 244-248. doi: 10.1002/1097-0142(19930701)72:13.0.co;2-q.
95. Chan MM, Chan MM, Mengshol JA, Fish DN, Chan ED,. Octreotide. Chest. 2013; 144 (6): 1937-1945. doi: 10.1378/chest.13-0382.
96. Faiss S,. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003; 21 (14): 2689-2696. doi: 10.1200/JCO.2003.12.142.
97. Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006; 47 (3): 502-511.
98. Reubi JC,. Old and new peptide receptor targets in cancer: future directions. Recent Results Cancer Res. 2013; 194 (Chapter 34): 567-576. doi: 10.1007/978-3-642-27994-2-34.
99. Ginj MM, Zhang HH, Waser BB, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. PNAS. 2006; 103 (44): 16436-16441. doi: 10.1073/pnas.0607761103.
100. Breeman WAP, De Jong M, Bernard BF, et al. Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer. 1999; 83 (5): 657-663. doi: 10.1002/(SICI)1097-0215(19991126)83:53.0.CO;2-Y.
101. Nicolas G, Giovacchini G, Müller-Brand J, Forrer F,. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin North Am. 2011; 40 (1): 187-204-ix-x. doi: 10.1016/j.ecl.2010.12.006.
102. Aranda F, Vacchelli E, Eggermont A, et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology. 2013; 2 (12): e26621. doi: 10.4161/onci.26621.
103. Kirkin AF, thor Straten P, Hansen MR, Barfoed A, Dzhandzhugazyan KN, Zeuthen J,. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones. Cancer Immunol Immunother. 1999; 48 (5): 239-246.
104. Di Pucchio T, Pilla L, Capone I, et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res. 2006; 66 (9): 4943-4951. doi: 10.1158/0008-5472.CAN-05-3396.
105. Zhang Y, Chaux P, Stroobant V, et al. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol. 2003; 171 (1): 219-225.
106. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994; 179 (3): 921-930.
107. Connerotte T, Van Pel A, Godelaine D, et al. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 2008; 68 (10): 3931-3940. doi: 10.1158/0008-5472.CAN-07-5898.
108. Schultz ES, Chapiro J, Lurquin C, et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med. 2002; 195 (4): 391-399.
109. Knutson KL, Schiffman K, Disis ML,. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001; 107 (4): 477-484. doi: 10.1172/JCI11752.
110. Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 2005; 25 (5): 3575-3579.
111. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005; 54 (3): 254-264. doi: 10.1007/s00262-004-0581-1.
112. Grunnet M, Sorensen JB,. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012; 76 (2): 138-143. doi: 10.1016/j.lungcan.2011.11.012.
113. Weiner LM,. Cancer immunotherapy-The endgame begins. N Engl J Med. 2008; 358 (25): 2664-2665. doi: 10.1056/NEJMp0803663.
114. Zitzmann S, Ehemann V, Schwab M,. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002; 62 (18): 5139-5143.
115. Temming K, Schiffelers RM, Molema G, Kok RJ,. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat. 2005; 8 (6): 381-402. doi: 10.1016/j.drup.2005.10.002.
116. Laakkonen P, Vuorinen K,. Homing peptides as targeted delivery vehicles. Integr Biol (Camb). 2010; 2 (7-8): 326-337. doi: 10.1039/c0ib00013b.
117. Pasqualini R, Ruoslahti E,. Organ targeting in vivo using phage display peptide libraries. Nature. 1996; 380 (6572): 364-366. doi: 10.1038/380364a0.
118. Koivistoinen A, Ilonen IIK, Punakivi K, et al. A novel peptide (Thx) homing to non-small cell lung cancer identified by ex vivo phage display. Clin Transl Oncol. 2013; 15 (6): 492-498. doi: 10.1007/s12094-012-0959-z.
119. Toba M, Alzoubi A, O'Neill K, et al. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension. Am J Pathol. 2014; 184 (2): 369-375. doi: 10.1016/j.ajpath.2013.10.008.
120. Svensen N, Walton JGA, Bradley M,. Peptides for cell-selective drug delivery. Trends Pharmacol Sci. 2012; 33 (4): 186-192. doi: 10.1016/j.tips.2012.02.002.
121. Chen K, Chen X,. Integrin targeted delivery of chemotherapeutics. Theranostics. 2011; 1: 189-200.
122. Garanger E, Boturyn D, Dumy P,. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anti-Cancer Agents Med Chem. 2007; 7 (5): 552-558. doi: 10.2174/187152007781668706.
123. Wagstaff KM, Jans DA,. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem. 2006; 13 (12): 1371-1387.
124. Green M, Loewenstein PM,. Autonomous functional domains of chemically synthesized human immunodeficiency virus tattrans-activator protein. Cell. 1988; 55 (6): 1179-1188. doi: 10.1016/0092-8674(88)90262-0.
125. Farkhani SM, Valizadeh A, Karami H, Mohammadi S, Sohrabi N, Badrzadeh F,. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides. 2014; 57: 78-94. doi: 10.1016/j.peptides.2014.04.015.
126. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A,. Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent. J Biol Chem. 1996; 271 (30): 18188-18193.
127. Bolhassani A,. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta. 2011; 1816 (2): 232-246. doi: 10.1016/j.bbcan.2011.07.006.
128. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA,. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. PNAS. 2008; 105 (34): 12128-12133. doi: 10.1073/pnas.0805374105.
129. Liou JS, Liu BR, Martin AL, Huang YW, Chiang HJ,. Protein transduction in human cells is enhanced by cell-penetrating peptides fused with an endosomolytic HA2 sequence. Peptides. 2012; 37 (2): 273-284. doi: 10.1016/j.peptides.2012.07.019.
130. Aroui S, Brahim S, De Waard M, Bréard J, Kenani A,. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. Cancer Lett. 2009; 285 (1): 28-38. doi: 10.1016/j.canlet.2009.04.044.
131. Nakase I, Konishi Y, Ueda M, Saji H, Futaki S,. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J Control Release. 2012; 159 (2): 181-188. doi: 10.1016/j.jconrel.2012.01.016.
132. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP,. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011; 11 (3): 239-253.
133. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 2005; 65 (24): 11658-11666. doi: 10.1158/0008-5472.CAN-05-2370.
134. Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR,. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem. 2012; 19 (22): 3794-3804. doi: 10.2174/092986712801661004.
135. Richter A, Eggenstein E, Skerra A, Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett. 2014; 588 (2): 213-218. doi: 10.1016/j.febslet.2013.11.006.
136. Emanuel SL, Engle LJ, Chao G, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. mabs. 2011; 3 (1): 38-48.
137. Boersma YL, Chao G, Steiner D, Wittrup KD, Plückthun A,. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem. 2011; 286 (48): 41273-41285. doi: 10.1074/jbc.M111.293266.
138. Silverman J, Lu Q, Bakker A, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol. 2005; 23 (12): 1556-1561. doi: 10.1038/nbt1166.
139. Beste G, Schmidt FS, Stibora T, Skerra A,. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. PNAS. 1999; 96 (5): 1898-1903.
140. Skerra A,. Lipocalins as a scaffold. Biochim Biophys Acta. 2000; 1482 (1-2): 337-350.
141. Skerra A,. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol. 2007; 18 (4): 295-304. doi: 10.1016/j.copbio.2007.04.010.
142. Skerra A,. Alternative binding proteins: anticalins-harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. 2008; 275 (11): 2677-2683. doi: 10.1111/j.1742-4658.2008.06439.x.
143. Schönfeld D, Matschiner G, Chatwell L, et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. PNAS. 2009; 106 (20): 8198-8203. doi: 10.1073/pnas.0813399106.
144. Gebauer M, Skerra A,. Anticalins small engineered binding proteins based on the lipocalin scaffold. Meth Enzymol. 2012; 503: 157-188. doi: 10.1016/B978-0-12-396962-0.00007-0.
145. Schlehuber S, Skerra A,. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol Chem. 2001; 382 (9): 1335-1342.
146. Koide A, Bailey CW, Huang X, Koide S,. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol. 1998; 284 (4): 1141-1151. doi: 10.1006/jmbi.1998.2238.
147. Koide A, Wojcik J, Gilbreth RN, Hoey RJ, Koide S,. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol. 2012; 415 (2): 393-405. doi: 10.1016/j.jmb.2011.12.019.
148. Hackel BJ, Kapila A, Wittrup KD,. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol. 2008; 381 (5): 1238-1252. doi: 10.1016/j.jmb.2008.06.051.
149. Hackel BJ, Wittrup KD,. The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Eng Des Sel. 2010; 23 (4): 211-219. doi: 10.1093/protein/gzp083.
150. Tolcher AW, Sweeney CJ, Papadopoulos K, et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res. 2011; 17 (2): 363-371. doi: 10.1158/1078-0432.CCR-10-1411.
151. Dineen SP, Sullivan LA, Beck AW, et al. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer. 2008; 8 (1): 352. doi: 10.1186/1471-2407-8-352.
152. Schiff D, Reardon D, Kesari S, Mikkelsen T,. Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). J Clin Oncol. 2010; 28 (15 suppl): 182s.
153. Chen TF, de Picciotto S, Hackel BJ, Wittrup KD,. Engineering fibronectin-based binding proteins by yeast surface display. Meth Enzymol. 2013; 523: 303-326. doi: 10.1016/B978-0-12-394292-0.00014-X.
154. Main ER, Lowe AR, Mochrie SG, Jackson SE, Regan L,. A recurring theme in protein engineering: the design, stability and folding of repeat proteins. Curr Opin Struct Biol. 2005; 15 (4): 464-471. doi: 10.1016/j.sbi.2005.07.003.
155. Winkler J, Martin-Killias P, Plückthun A, Zangemeister-Wittke U,. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther. 2009; 8 (9): 2674-2683. doi: 10.1158/1535-7163.MCT-09-0402.
156. Patricia M-KM, Stefan NN, Rothschild SS, Plückthun AA, Zangemeister-Wittke UU,. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res. 2011; 17 (1): 100-110. doi: 10.1158/1078-0432.CCR-10-1303.
157. Wolf S, Souied EH, Mauget-Faysse M, Devin F, Patel M,. Phase I MP0112 wet AMD study: results of a single escalating dose study with DARPin MP0112 in wet AMD. Invest Ophthalmol Vis Sci. 2011; 52. E-Abstract 3541.
158. Coiffier BB, Haioun CC, Ketterer NN, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998; 92 (6): 1927-1932.
159. Coiffier B, et al. CHOP plus rituximab with CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma: a groupe D"Etude Des Lymphomes De L"Adulte Study. N Engl J Med. 2002; 346: 235-242. http://scholar.google.com/scholar?q=related:gZW8o2GAIEgJ:scholar.google.com/&hl=en&num=20&as-sdt=0,5.
160. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105 (4): 1417-1423. doi: 10.1182/blood-2004-08-3175.
161. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011; 12 (11): 1013-1022. doi: 10.1016/S1470-2045(11)70235-2.
162. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112 (4): 975-980. doi: 10.1182/blood-2008-02-140582.
163. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab As single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010; 28 (10): 1749-1755.
164. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared With chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007; 25 (35): 5616-5623. doi: 10.1200/JCO.2007.12.9098.
165. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344 (11): 783-792. doi: 10.1056/NEJM200103153441101.
166. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC,. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010; 376 (9742): 687-697. doi: 10.1016/S0140-6736(10)61121-X.
167. Swain SM, Kim S-B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14 (6): 461-471. doi: 10.1016/S1470-2045(13)70130-X.
168. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27 (5): 663-671. doi: 10.1200/JCO.2008.20.8397.
169. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11 (1): 21-28. doi: 10.1016/S1470-2045(09)70311-0.
170. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359 (11): 1116-1127. doi: 10.1056/NEJMoa0802656.
171. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373 (9674): 1525-1531. doi: 10.1016/S0140-6736(09)60569-9.
172. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25 (13): 1658-1664. doi: 10.1200/JCO.2006.08.1620.
173. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008; 26 (21): 3523-3529. doi: 10.1200/JCO.2007.15.4138.
174. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13 (4): 1253-1259. doi: 10.1158/1078-0432.CCR-06-2309.
175. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30 (28): 3499-3506.
176. Stopeck AT, Lipton A, Body J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28 (35): 5132-5139.
177. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007; 25 (30): 4779-4786. doi: 10.1200/JCO.2007.11.3357.
178. Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol. 2014; 32 (3s). Abstract 4076.
179. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367 (19): 1783-1791. doi: 10.1056/NEJMoa1209124.
180. Riedell P, Carson KR,. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf. 2014; 13 (7): 977-987. doi: 10.1517/14740338.2014.918948.
181. Hagenbeek A, Fayad L, Delwail V, et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. ASH Ann. 2009; 114. Abstract 935.
182. Coiffier B, Losic N, Rønn BB, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol. 2010; 150 (1): 58-71. doi: 10.1111/j.1365-2141.2010.08193.x.
183. Østergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 2010; 62 (8): 2227-2238. doi: 10.1002/art.27524.
184. Ujjani C, Ramzi P, Gehan E, Wang H, Wang Y, Cheson BD,. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma [published online ahead of print 2014]. Leuk Lymphoma. doi: 10.3109/10428194.2014.933217.
185. Hale G, Rebello P, Brettman LR, Fegan C,. Blood concentrations of alemtuzumab and antiglobin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004; 104: 948-955.
186. Aranha AA, Amer S, Reda ES, Broadley SA, Davoren PM,. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review. Endocr Pract. 2013; 19 (5): 821-828. doi: 10.4158/EP13020.RA.
187. Bruno R, Washington CB, Lu J-F, Lieberman G, Banken L, Klein P,. Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005; 56 (4): 361-369. doi: 10.1007/s00280-005-1026-z.
188. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353 (16): 1659-1672. doi: 10.1056/NEJMoa052306.
189. Yamamoto N, Yamada Y, Fujiwara Y, et al. Phase I pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol. 2009; 39 (4): 260-266. doi: 10.1093/jjco/hyp006.
190. Garg A, Li J, Clark E, et al. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol. 2013; 72 (5): 1133-1141. doi: 10.1007/s00280-013-2279-6.
191. Keating GM,. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs. 2012; 72 (3): 353-360. doi: 10.2165/11209000-000000000-00000.
192. Tan AR, Moore DF, Hidalgo M, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res. 2006; 12 (21): 6517-6522. doi: 10.1158/1078-0432.CCR-06-0705.
193. Yang B-B, Lum P, Chen A, et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet. 2010; 49 (11): 729-740. doi: 10.2165/11535970-000000000-00000.
194. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R,. FDA drug approval summary: panitumumab (Vectibix). Oncologist. 2007; 12 (5): 577-583. doi: 10.1634/theoncologist.12-5-577.
195. Lu J-F, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J,. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008; 62 (5): 779-786. doi: 10.1007/s00280-007-0664-8.
196. Tang PA, Cohen SJ, Kollmannsberger C, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res. 2012; 18 (21): 6023-6031. doi: 10.1158/1078-0432.CCR-11-3252.
197. Sohn W, Simiens MA, Jaeger K, Hutton S, Jang G,. The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. Br J Clin Pharmacol. 2014; 78 (3): 477-487.
198. Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009; 182 (6): 2670-2675. doi: 10.1016/j.juro.2009.08.048.
199. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010; 28 (5): 780-787. doi: 10.1200/JCO.2009.23.7537.
200. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003; 44 (3): 465-474.
201. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003; 21 (7): 1263-1270.
202. Firer MA, Gellerman G,. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012; 5: 70-70. doi: 10.1186/1756-8722-5-70.
203. Furtado M, Rule S,. Emerging pharmacotherapy for relapsed or refractory Hodgkin's lymphoma: focus on brentuximab vedotin. CMO. 2012; 2012 (6): 31-39. doi: 10.4137/CMO.S6637.
204. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010; 28 (16): 2698-2704. doi: 10.1200/JCO.2009.26.2071.
205. Cochlovius B, Kipriyanov SM, Stassar MJ, et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res. 2000; 60 (16): 4336-4341.
206. Batori V, Koide A, Koide S,. Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. Protein Eng. 2002; 15 (12): 1015-1020.
207. Boersma YL, Plückthun A,. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol. 2011; 22 (6): 849-857. doi: 10.1016/j.copbio.2011.06.004.